IPO发行：Aligos Therapeutics准备在美国进行1.5亿美元的IPO

StephenW

IPO Launch: Aligos Therapeutics Readies $150 Million U.S. IPO

IPOStreet

16 hours ago

Aligos Therapeutics (ALGS) intends to raise $150 million in an IPO of its common stock, according to an S-1 registration statement.

South San Francisco, California-based Aligos was founded to develop a functional cure for Hepatitis B and other liver and viral diseases.

Management is headed by co-founder and CEO Mr. Lawrence Blatt, Ph.D., who was previously Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson (JNJ).
IPO发行：Aligos Therapeutics准备在美国进行1.5亿美元的IPO

知识产权局

16小时前

根据S-1注册声明，Aligos Therapeutics（ALGS）打算通过首次公开募股筹集1.5亿美元。

成立于加利福尼亚州南旧金山的Aligos成立是为了开发针对乙型肝炎以及其他肝脏和病毒性疾病的功能性疗法。

管理层由联合创始人兼首席执行官Lawrence Blatt博士领导，他曾是强生（JNJ）子公司Janssen Pharmaceutical Companies的传染病和疫苗全球主管。

https://www.thestreet.com/ipo/news/aligos-therapeutics-ipo-launch